Home
>
National Drug Code (NDC)
>
Avastin
Avastin - 50242-061-01 - (bevacizumab)
Drug Information of Avastin
| Product NDC: | 50242-061 |
| Proprietary Name: | Avastin |
| Non Proprietary Name: | bevacizumab |
| Active Ingredient(s): | 400 mg/16mL & nbsp; bevacizumab |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION, SOLUTION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Avastin
| Product NDC: | 50242-061 |
| Labeler Name: | Genentech, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | BLA125085 |
| Marketing Category: | BLA |
| Start Marketing Date: | 20040226 |
Package Information of Avastin
| Package NDC: | 50242-061-01 |
| Package Description: | 1 VIAL, SINGLE-USE in 1 CARTON (50242-061-01) > 16 mL in 1 VIAL, SINGLE-USE |
NDC Information of Avastin
| NDC Code | 50242-061-01 |
| Proprietary Name | Avastin |
| Package Description | 1 VIAL, SINGLE-USE in 1 CARTON (50242-061-01) > 16 mL in 1 VIAL, SINGLE-USE |
| Product NDC | 50242-061 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | bevacizumab |
| Dosage Form Name | INJECTION, SOLUTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 20040226 |
| Marketing Category Name | BLA |
| Labeler Name | Genentech, Inc. |
| Substance Name | BEVACIZUMAB |
| Strength Number | 400 |
| Strength Unit | mg/16mL |
| Pharmaceutical Classes | Vascular Endothelial Growth Factor Receptor Inhibitors [MoA],Vascular Endothelial Growth Factor-directed Antibody [EPC],Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA] |
